Tunable separation of anions and cations by column switching in ion chromatography.

M. Amin,L. Lim,T. Takeuchi

DOI: https://doi.org/10.1016/j.talanta.2006.07.020

2007-03-15

Abstract:

What problem does this paper attempt to address?

Diabetes and cognitive impairment: how to evaluate the cognitive status?

F. Pasquier

DOI: https://doi.org/10.1016/s1262-3636(10)70475-4

2010-10-01

Abstract:AIM: Patients with diabetes have shown lower performance in tests of cognitive function especially those testing memory, executive functions, and psychomotor efficiency. They also have an elevated risk of both vascular dementia and Alzheimer's disease. Cognitive impairment may have consequence on treatment compliance.METHODS AND RESULTS: This article provides indication for holding an interview, and reports a few screening bedside tests to detect a cognitive impairment. Some neuropsychological tests useful for characterizing the cognitive profile of a patient are described, as well as the main cognitive profiles expected in patients with diabetes and cognitive decline.CONCLUSION: A systematic assessment of cognition with a rapid interview and screening tests in patients with diabetes, especially the oldest, with a long history of diabetes, co-morbidities, or with unexplained poor metabolic control would be a good clinical practice. Patients with cognitive decline may be referred to memory clinics for identifying the cause of the decline and contribute to provide appropriate medical and medicosocial management.

endocrinology & metabolism
Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications

Geert Jan Biessels,Florin Despa

DOI: https://doi.org/10.1038/s41574-018-0048-7

2018-07-18

Nature Reviews Endocrinology

Abstract:Cognitive dysfunction is increasingly recognized as an important comorbidity of diabetes mellitus. Different stages of diabetes-associated cognitive dysfunction exist, each with different cognitive features, affected age groups and prognoses and probably with different underlying mechanisms. Relatively subtle, slowly progressive cognitive decrements occur in all age groups. More severe stages, particularly mild cognitive impairment and dementia, with progressive deficits, occur primarily in older individuals (>65 years of age). Patients in the latter group are the most relevant for patient management and are the focus of this Review. Here, we review the evolving insights from studies on risk factors, brain imaging and neuropathology, which provide important clues on mechanisms of both the subtle cognitive decrements and the more severe stages of cognitive dysfunction. In the majority of patients, the cognitive phenotype is probably defined by multiple aetiologies. Although both the risk of clinically diagnosed Alzheimer disease and that of vascular dementia is increased in association with diabetes, the cerebral burden of the prototypical pathologies of Alzheimer disease (such as neurofibrillary tangles and neuritic plaques) is not. A major challenge for researchers is to pinpoint from the spectrum of diabetes-related disease processes those that affect the brain and contribute to development of dementia beyond the pathologies of Alzheimer disease. Observations from experimental models can help to meet that challenge, but this requires further improving the synergy between experimental and clinical scientists. The development of targeted treatment and preventive strategies will therefore depend on these translational efforts.

endocrinology & metabolism
Cognitive Dysfunction in Older Adults With Diabetes: What a Clinician Needs to Know

Medha N Munshi

DOI: https://doi.org/10.2337/dc16-1229

Diabetes Care

Abstract:One of the challenges of managing older adults with diabetes is the individualization of care in people with multiple comorbid conditions. Although macrovascular and microvascular complications of diabetes are well recognized, there is a lack of awareness regarding other conditions such as cognitive dysfunction, depression, and physical disabilities. Cognitive dysfunction is of particular importance because of its impact on self-care and quality of life. In this Perspective, I discuss common and practical questions faced by clinicians managing diabetes in older adults who also have cognitive dysfunction.
Application of cognitive screening guidelines by health care providers in diabetes care: A cross-sectional descriptive study

Heather Cuevas,Catherine Ward

DOI: https://doi.org/10.1111/jep.13085

Abstract:Rationale, aims, and objectives: The risk of cognitive dysfunction is higher in people with diabetes than in the general population, and approximately 50% of those with diabetes will develop cognitive impairments as they age. Screening for cognitive dysfunction in people with diabetes can help identify both pathology and those who are at risk for higher health care utilization, but we do not know how health care providers implement cognitive screening recommendations in this population. In this study, we examined health care providers' knowledge of those recommendations and their application of them, as well as factors associated with guideline use. Methods: This study used a cross-sectional, descriptive correlational design with a convenience sample. All data were collected with a 20-question online survey sent to advanced practice nurses (APNs), medical doctors/doctor of osteopathic medicines (MDs/DOs), and physician assistants (PAs) in Central Texas. Results: One-hundred eighty-one health care providers responded. Participants most frequently said they were "moderately familiar" with guidelines for cognitive impairment screening (60.9%). Twenty-three per cent of physicians, 37.4% of APNs, and 8.3% of PAs indicated that they incorporated routine screening into daily practice. However, 64% did not use standardized tools to assess cognitive function. The most common clinical tasks related to cognitive screening were referral for more in-depth cognitive screening (44%) and education of families regarding cognitive problems (29%). Lack of time was the most common barrier to screening (57.7%). Conclusions: Most respondents believed that there was a good rationale for assessing cognitive function in people with diabetes. However, despite some familiarity with guidelines for cognitive function screening, most respondents did not use standardized assessment tools. The results indicate variability in clinical practice regarding assessment and practices, such that there may be some variability in outcomes for patients.
Cognitive Dysfunction in Older Adults with Type 2 Diabetes: Links, Risks, and Clinical Implications

Alan Sinclair,Ahmed Abdelhafiz

DOI: https://doi.org/10.1016/j.cger.2020.04.002

Abstract:The prevalence of comorbid diabetes and cognitive dysfunction increases as the population ages. Diabetes increases the risk of progression of cognitive dysfunction through a spectrum of cognitive decline to mild cognitive impairment then to dementia. Cognitive dysfunction, especially impairment in the executive domain, has a negative impact on patients' self-care tasks. With further progression of dementia and the development of behavioral problems, the challenge to carers and health care professionals looking after these patients is significant. Therefore, clinical trials are needed to explore the impact of novel hypoglycemic therapy on cognitive function as an important outcome in this population.
Type 2 diabetes mellitus and cognitive function: understanding the connections

Lisa Dao,Sarah Choi,Matthew Freeby

DOI: https://doi.org/10.1097/MED.0000000000000783

2023-02-01

Abstract:Purpose of review: To review the connection between type 2 diabetes and cognitive dysfunction, including its epidemiology, potential mechanisms of pathophysiology, risk factors, possible prevention, and treatment considerations. Recent findings: Diabetes is a risk factor for mild cognitive decline, in addition to Alzheimer's disease and vascular dementia. Duration of diabetes, concomitant vascular or associated co-morbidities, hyper- and hypoglycemia may lead to worsening cognitive dysfunction. Unfortunately, there is a lack of evidence-based guidance on the prevention of cognitive dysfunction in the diabetes population. Studies of diabetes medications, including metformin, glucagon-like peptide-1 (GLP-1) receptor agonists, and sodium-glucose cotransporter-2 inhibitors (SGLT2) have shown some benefit with cardiovascular morbidity and may affect cognition. In the absence of clearly defined preventive tools, diabetes practice guidelines recommend annual cognitive screening as standard of care in adults with diabetes aged 65 years or older. Summary: People living with diabetes are at risk for significant decline in cognitive function. Epidemiology and risk factors are well defined. Prevention and treatment strategies are limited and require further study.
The mechanism and treatment of cognitive dysfunction in diabetes: A review

Yangbo Hou,Jiwei Cheng,Zhen Chen,Lu Yin,Guoyi Li,Jie Gao

DOI: https://doi.org/10.1055/a-2480-7826

2024-11-21

Abstract:Diabetes mellitus (DM) is one of the fastest growing diseases in terms of incidence worldwide and seriously affects cognitive function. The incidence rate of cognitive dysfunction is up to 13% in diabetes patients aged 65-74 and reaches 24% in those aged >75 years. The mechanisms and treatments of cognitive dysfunction associated with diabetes mellitus are complicated and varied. According to previous studies, hyperglycaemia mainly contributes to cognitive dysfunction through mechanisms involving inflammation, autophagy, the microbial-gut-brain axis, brain-derived neurotrophic factors and insulin resistance. Antidiabetic drugs such as metformin, liraglutide and empagliflozin and other drugs such as fingolimod and melatonin can alleviate cognitive dysfunction caused by diabetes. Self-management, indirect fasting and repetitive transverse magnetic stimulation can also ameliorate cognitive impairment. In this review, we discuss the mechanisms linking diabetes mellitus with cognitive dysfunction and propose a potential treatment for cognitive dysfunction related to diabetes mellitus.
Diabetes and cognitive function: An evidence-based current perspective

Meghna Julian Sebastian,Shahanas KA Khan,Joseph M Pappachan,Mohammad Sadiq Jeeyavudeen

DOI: https://doi.org/10.4239/wjd.v14.i2.92

2023-02-16

World Journal of Diabetes

Abstract:Several epidemiological studies have clearly identified diabetes mellitus (DM) as a major risk factor for cognitive dysfunction, and it is going to be a major public health issue in the coming years because of the alarming rise in diabetes prevalence across the world. Brain and neural tissues predominantly depend on glucose as energy substrate and hence, any alterations in carbohydrate meta-bolism can directly impact on cerebral functional output including cognition, executive capacity, and memory. DM affects neuronal function and mental capacity in several ways, some of which include hypoperfusion of the brain tissues from cerebrovascular disease, diabetes-related alterations of glucose transporters causing abnormalities in neuronal glucose uptake and metabolism, local hyper- and hypometabolism of brain areas from insulin resistance, and recurrent hypoglycemic episodes inherent to pharmacotherapy of diabetes resulting in neuronal damage. Cognitive decline can further worsen diabetes care as DM is a disease largely self-managed by patients. Therefore, it is crucial to understand the pathobiology of cognitive dysfunction in relation to DM and its management for optimal long-term care plan for patients. A thorough appraisal of normal metabolic characteristics of the brain, how alterations in neural metabolism affects cognition, the diagnostic algorithm for patients with diabetes and dementia, and the management and prognosis of patients when they have this dangerous combination of illnesses is imperative in this context. This evidence-based narrative with the back-up of latest clinical trial reviews elaborates the current understanding on diabetes and cognitive function to empower physicians to manage their patients in day-to-day clinical practice. Key Words: Diabetes mellitus, Dementia, Cognitive function, Antidiabetic medications, Hyperglycemia, Hypoglycemia Core Tip: Diabetes mellitus (DM) is a huge risk factor for cognitive dysfunction especially when the glycemic control is inadequate with marked hyperglycemia and recurrent hypoglycemia. Apart from cognitive decline inherent to the disease, presence of other forms of dementia can adversely affect diabetes control and consequently, negatively impact the care of dementia and DM. Appropriate control of DM with a multidisciplinary team approach involving diabetologists, dementia specialists, dieticians and physiotherapists should improve the clinical outcomes of either disease. Judicious and evidence-based adjustments in the antidiabetic medications appropriately tailored for individualised diabetes care with due consideration of patient's age, severity of dementia and other comorbidities should help to improve care of patients with diabetes and dementia. Citation: Sebastian MJ, Khan SK, Pappachan JM, Jeeyavudeen MS. Diabetes and cognitive function: An evidence-based current perspective. World J Diabetes 2023; 14(2): 92-109 URL: https://www.wjgnet.com/1948-9358/full/v14/i2/92.htm DOI: https://dx.doi.org/10.4239/wjd.v14.i2.92

endocrinology & metabolism
Cognitive impairment in diabetic patients: Can diabetic control prevent cognitive decline?

Takahiko Kawamura,Toshitaka Umemura,Nigishi Hotta

DOI: https://doi.org/10.1111/j.2040-1124.2012.00234.x

2012-08-29

Journal of Diabetes Investigation

Abstract:It is well recognized that the prevalence of dementia is higher in diabetic patients than non-diabetic subjects. The incidence of diabetes has been increasing because of dramatic changes in lifestyles, and combined with longer lifespans as a result of advances in medical technology, this has brought about an increase in the number of elderly diabetic patients. Together, aging and diabetes have contributed to dementia becoming a serious problem. Progression to dementia reduces quality of life, and imposes a burden on both patients themselves and the families supporting them. Therefore, preventing the complication of dementia will become more and more important in the future. Although many mechanisms have been considered for an association between diabetes and cognitive dysfunction, glucose metabolism abnormalities such as hyperglycemia and hypoglycemia, and insulin action abnormalities such as insulin deficiency and insulin resistance can be causes of cognitive impairment. Recent large-scale longitudinal studies have found an association between glycemic control and cognitive decline, although it is still unclear how cognitive decline might be prevented by good glycemic control. However, at an early stage, it is necessary to detect moderate cognitive dysfunction and try to reduce the risk factors for it, which should result in prevention of dementia, as well as vascular events. In the present review, in addition to outlining an association between diabetes and cognitive function, we discuss how glycemic control and cognitive decline are related.

endocrinology & metabolism
Cognitive dysfunction in diabetes-related foot complications: A cohort study

Mai Loan Nguyen,Dana Wong,Elizabeth Barson,Eva Staunton,Caroline A Fisher

DOI: https://doi.org/10.1007/s40200-023-01381-4

2024-01-22

Abstract:Objective: Mild-moderate cognitive impairment has been identified in general diabetes, and early evidence indicates cognitive reductions may be more pronounced in those with diabetes-related foot complications (DRFC). Cognitive difficulties may impede treatment engagement and self-management. This requires further explication to optimise patient care and outcomes. The current study aimed to characterise cognitive function in people with DRFC using comprehensive cognitive measures. Method: This cross-sectional cohort study recruited 80 adult participants (M age = 63.38, SD = 11.40, range = 30 - 89) from the Royal Melbourne Hospital Diabetic Foot Unit in Victoria, Australia, all with DRFC. Each completed a comprehensive cognitive battery (memory, attention, executive functions) and scores were calculated using age-matched population norms, where available. Results: On the majority of tasks, DRFC participants performed significantly worse than age-matched norms, with the largest decrements seen in inhibition control, verbal memory, verbal abstract reasoning and working memory. Small to moderate reductions were also seen in visual learning, verbal fluency, processing speed and premorbid functioning. Demographic (lower education, male gender) and clinical factors (higher HbA1c, macrovascular and microvascular disease, longer diabetes duration) were associated with poorer cognitive functioning. Conclusions: Marked reductions in cognitive functioning were found in individuals with DRFC, predominantly in the domains of verbal memory and executive functioning. Lower education, male gender and indicators of diabetes severity, such as vascular disease, are associated with heightened risk for poorer cognitive functioning. As DRFCs are a serious complication with devastating outcomes if not successfully managed, cognitive barriers to self-management must be addressed to optimise treatment. Supplementary information: The online version contains supplementary material available at 10.1007/s40200-023-01381-4.
The impact of diabetes in cognitive impairment: A review of current evidence and prospects for future investigations

Nicholas Aderinto,Gbolahan Olatunji,Muili Abdulbasit,Patrick Ashinze,Olamide Faturoti,Abayomi Ajagbe,Bonaventure Ukoaka,Gbolahan Aboderin

DOI: https://doi.org/10.1097/md.0000000000035557

IF: 1.6

2024-02-10

Medicine

Abstract:In recent years, diabetes mellitus has transitioned from a medical concern primarily associated with metabolic disturbances to a complex condition with potential implications far beyond glycemic control. [ 1 ] As the prevalence of diabetes continues to rise globally, a growing body of research has begun to highlight its potential impact on cognitive function. [ 2 ] Diabetes, characterized by the body inability to regulate blood glucose levels effectively, is well-known for its associated complications, including cardiovascular disease, neuropathy, and retinopathy. [ 3 ] However, a lesser-explored aspect is its potential influence on cognitive abilities. Cognitive impairment, encompassing deficits in memory, attention, language, and executive function, represents a significant challenge to affected individuals, their families, and healthcare providers. [ 4 ]

medicine, general & internal
Optimisation of retroviral supernatant production conditions for the genetic modification of human CD34+ cells

J. Dando,A. Aiuti,S. Deola,F. Ficara,C. Bordignon

DOI: https://doi.org/10.1002/1521-2254(200105/06)3:3<219::AID-JGM184>3.0.CO;2-E

2001-05-01

Abstract:Clinically applicable protocols for ex vivo modification of human CD34+ hematopoietic stem/progenitor cells rely on incubation of the target cell with supernatant containing recombinant retroviral particles. Although components of the supernatant may have a profound impact on both preclinical and clinical outcome, to date supernatant production has not been properly addressed with regard to CD34+ cells. We wanted to investigate and optimise production conditions for this target using simple, reproducible and clinically applicable procedures and reagents.
Perceptions and responses to cognitive decline in people with diabetes: A systematic review of qualitative studies

Meijuan Wang,Xiangyun Guan,Jingzheng Yan,Nyagwaswa Michael,Xueyan Liu,Ran Tan,Xiaoyan Lv,Fei Yan,Yingjuan Cao

DOI: https://doi.org/10.3389/fpubh.2023.1076030

IF: 5.2

2023-01-01

Frontiers in Public Health

Abstract:ObjectiveWe aimed at summarizing the perceptions and responses to cognitive decline, assessing the disease management, identifying deficiencies and proposing new strategies for improvement in people with diabetes (PWDs). MethodsA comprehensive search was performed in the following nine databases: PubMed, EMBASE, Web of Science, The Cochrane Library, PsycINFO, CINAHL, WanFang, CNKI, and VIP. The Joanna Briggs Institute (JBI) Critical Appraisal Tool for qualitative research was utilized to evaluate the quality of included studies. Descriptive texts and quotations relating to patient experience were extracted from the included studies and thematically analyzed. ResultsEight qualitative studies met the inclusion criteria and 2 overarching themes were identified: (1) self-perception of cognitive decline referred to perceived cognitive symptoms, lack of knowledge and, impaired self-management and coping in multiple methods; (2) reported benefits of cognitive interventions referred to how cognitive interventions improved disease management, attitudes and needs of PWDs. ConclusionPWDs described misconceptions about their cognitive decline and suffered from them during disease management. This study provides a patient-specific reference for cognitive screening and intervention in PWDs, supporting disease management with cognitive decline in clinical practice.
The Relationship between Impaired Glucose Tolerance, Type 2 Diabetes, and Cognitive Function

Nesrine Awad,Michèle Gagnon,Claude Messier

DOI: https://doi.org/10.1080/13803390490514875

2004-11-01

Journal of Clinical and Experimental Neuropsychology

Abstract:The present review integrates findings of published studies that have evaluated the cognitive function of treated and untreated type 2 diabetic patients and provides a detailed overview of the neuropsychological assessments conducted. Cognitive deficits are observed in older people with glucose intolerance or untreated diabetes but these deficits appear to be attenuated by treatments that improve glycemic control. Cognitive decrements in treated type 2 diabetic patients are most consistently observed on measures of verbal memory (35% of the measures) and processing speed (45% of the measures) while preserved function is observed on measures of visuospatial, attention, semantic and language function. Some studies suggest that deficits in cognitive functions are associated with poorer glycemic control. A number of other factors, such as depression, cardiovascular and cerebrovascular disease, increase these deficits. We conclude that, in diabetic patients who achieve and maintain good glycemic control, type 2 diabetes only has a small impact on cognitive functions before the age of 70 years. However, early onset of type 2 diabetes, poor glycemic control and the presence of micro- and macrovascular disease may interact to produce early cognitive deficits. In older adults (70 years and over), diabetes likely interacts with other dementing processes such as vascular disease and Alzheimer's disease to hasten cognitive decline.

psychology, clinical,clinical neurology
Cognitive impairment and associated factors among patients with diabetes mellitus in Africa: a systematic review and meta-analysis

Worku Chekol Tassew,Yeshiwas Ayal Ferede,Agerie Mengistie Zeleke

DOI: https://doi.org/10.3389/fendo.2024.1386600

IF: 6.055

2024-07-17

Frontiers in Endocrinology

Abstract:Background: Inappropriate management of blood sugar in patients with diabetes mellitus leads to micro-vascular and macro-vascular complications, subsequently leading to high morbidity and mortality rates. In addition, diabetes independently increases the occurrence of cognitive impairment complicated by dementia. Scientific evidence on the magnitude of cognitive impairment will provide a sound basis for the determination of healthcare needs and the planning of effective healthcare services. Despite this, there are no comprehensive data on the prevalence and associated factors of cognitive impairment among patients with diabetes in Africa. Methods: To identify relevant articles for this review, we searched PubMed, Cochrane Library, Science Direct, African Journals Online, and Google Scholar. After extraction, the data were imported into Stata software version 11 (Stata Corp., TX, USA) for further analysis. The random-effects model, specifically the DerSimonian and Laird (D+L) pooled estimation method, was used due to the high heterogeneity between the included articles. Begg's and Egger's regression tests were used to determine the evidence of publication bias. Sub-group analyses and sensitivity analyses were also conducted to handle heterogeneity. Results: The pooled prevalence of cognitive impairment among patients with diabetes in Africa is found to be 43.99% (95% CI: 30.15–57.83, p < 0.001). According to our analysis, primary level of education [pooled odds ratio (POR) = 6.08, 95% CI: 3.57–10.36, I 2 = 40.7%], poorly controlled diabetes mellitus (POR = 5.85, 95% CI: 1.64–20.92, I 2 = 87.8%), age above 60 years old (POR = 3.83, 95% 95% CI: 1.36–10.79, I 2 = 63.7%), and diabetes duration greater than 10 years (POR = 1.13; 95% CI: 1.07–1.19, I 2 = 0.0%) were factors associated with cognitive impairment among patients with diabetes. Conclusion: Based on our systematic review, individuals with diabetes mellitus exhibit a substantial prevalence rate (43.99%) of cognitive impairment. Cognitive impairment was found to be associated with factors such as primary level of education, poorly controlled diabetes mellitus, age above 60 years, and diabetes duration greater than 10 years. Developing suitable risk assessment tools is crucial to address uncontrolled hyperglycemia effectively. Systematic review registration: https://www.crd.york.ac.uk/prospero, identifier CRD42024561484.

endocrinology & metabolism
Cognitive dysfunction in diabetes: abnormal glucose metabolic regulation in the brain

Shan Zhang,Yueying Zhang,Zhige Wen,YaNan Yang,Tianjie Bu,Xiangwei Bu,Qing Ni

DOI: https://doi.org/10.3389/fendo.2023.1192602

IF: 6.055

2023-06-16

Frontiers in Endocrinology

Abstract:Cognitive dysfunction is increasingly recognized as a complication and comorbidity of diabetes, supported by evidence of abnormal brain structure and function. Although few mechanistic metabolic studies have shown clear pathophysiological links between diabetes and cognitive dysfunction, there are several plausible ways in which this connection may occur. Since, brain functions require a constant supply of glucose as an energy source, the brain may be more susceptible to abnormalities in glucose metabolism. Glucose metabolic abnormalities under diabetic conditions may play an important role in cognitive dysfunction by affecting glucose transport and reducing glucose metabolism. These changes, along with oxidative stress, inflammation, mitochondrial dysfunction, and other factors, can affect synaptic transmission, neural plasticity, and ultimately lead to impaired neuronal and cognitive function. Insulin signal triggers intracellular signal transduction that regulates glucose transport and metabolism. Insulin resistance, one hallmark of diabetes, has also been linked with impaired cerebral glucose metabolism in the brain. In this review, we conclude that glucose metabolic abnormalities play a critical role in the pathophysiological alterations underlying diabetic cognitive dysfunction (DCD), which is associated with multiple pathogenic factors such as oxidative stress, mitochondrial dysfunction, inflammation, and others. Brain insulin resistance is highly emphasized and characterized as an important pathogenic mechanism in the DCD.

endocrinology & metabolism
Mild Cognitive Impairment Screening in Older Adults With Type 2 DM

Daniela Victoria Pirela,Victor Cevallos,Jorge G Ruiz

DOI: https://doi.org/10.1210/jendso/bvab048.850

2021-05-01

Journal of the Endocrine Society

Abstract:Abstract Introduction: Older adults (O-A), more than 65 years old, are a heterogeneous group of patients in terms of functionality, social support and health status that implies a wide range of co-morbidities including mild cognitive impairment (MCI) and unidentified dementia. De-intensification of treatment is recommended for O-A with T2DM, tight glycemic control and high risk of hypoglycemia. Assessment of all geriatric domains (medical, functional, social and psychological including screening for MCI) is encouraged to support a complete clinical picture that leads to appropriate targets and adequate therapeutic approach. The literature suggests that de-intensification of treatment in this population is uncommon, which calls for the development of new strategies to prevent potential harm, however we also question if previously established tools are being used. Methods: We performed a retrospective chart review of a community-dwelling Veterans with at least two office visits in the Geriatric Clinic between January 1st 2018 to December 31st 2019. 210 patients with 65 years of age or older with T2DM and A1C < 7.5 were found. 64 (30%) of the patients where on hypoglycemic medication including sulfonylureas or insulin. From this subgroup, only 9 (14%) patients where recommended to de-intensify therapy. 189 (90%) of all the patients were screened for memory disorders. Interestingly 20 patients (31%) of those using sulfonylureas or insulin as part of their diabetes treatment were not screened, which was a higher percentage compared to 48 (25%) patients not on hypoglycemic medications also not screened for memory disorders. Conclusion: similar to previous studies de-intensification is uncommon not only among endocrinologist but in other sub-specialties involved in the care of the Geriatric population. This data emphasizes the importance of using previously developed treatment tools specially in those with at higher risk of overtreatment side effects such as older adults with tight glycemic control and hypoglycemic medication
[The role of candidate genes in susceptibility to diabetic nephropathy].

W. Grzeszczak,E. Zukowska-szczechowska

1997-06-01

Abstract:
[Experimental study of the effect of physiologically active combinations on the stimulation of reparative osteogenesis].

L. Mansurova,A. B. Skorniakova,V. B. Kazimirovskaia,L. E. Smolianko,V. V. Trofimov,M. Voronkov

Abstract:
Quantum transport through a periodic scatterer in a magnetic field.

Nonoyama,Nakamura

DOI: https://doi.org/10.1103/PHYSREVB.54.2635

1996-07-15

Abstract:A numerical method is described for the calculation of the conductance through a region where obstacles are placed in a quasi-one-dimensional quantum wire in a magnetic field. Using this method, we have studied the commensurability problem between a periodic potential and a magnetic field, laying stress on the interference effects of the electron waves on transport properties. Numerical calculations are performed for a rectangular antidot superlattice and a periodic double-parallel point contacts array. In the extreme quantum regime where a few Landau levels are filled, the Aharanov-Bohm type conductance oscillation appears clearly. In the case of the rectangular antidot lattice, it has been found that the conductivity has a characteristic structure due to the commensurability between the cyclotron radius and the period of the antidots. @S0163-1829 ~96!07524-8#

Tunable separation of anions and cations by column switching in ion chromatography.

Diabetes and cognitive impairment: how to evaluate the cognitive status?

Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications

Cognitive Dysfunction in Older Adults With Diabetes: What a Clinician Needs to Know

Application of cognitive screening guidelines by health care providers in diabetes care: A cross-sectional descriptive study

Cognitive Dysfunction in Older Adults with Type 2 Diabetes: Links, Risks, and Clinical Implications

Type 2 diabetes mellitus and cognitive function: understanding the connections

The mechanism and treatment of cognitive dysfunction in diabetes: A review

Diabetes and cognitive function: An evidence-based current perspective

Cognitive impairment in diabetic patients: Can diabetic control prevent cognitive decline?

Cognitive dysfunction in diabetes-related foot complications: A cohort study

The impact of diabetes in cognitive impairment: A review of current evidence and prospects for future investigations

Optimisation of retroviral supernatant production conditions for the genetic modification of human CD34+ cells

Perceptions and responses to cognitive decline in people with diabetes: A systematic review of qualitative studies

The Relationship between Impaired Glucose Tolerance, Type 2 Diabetes, and Cognitive Function

Cognitive impairment and associated factors among patients with diabetes mellitus in Africa: a systematic review and meta-analysis

Cognitive dysfunction in diabetes: abnormal glucose metabolic regulation in the brain

Mild Cognitive Impairment Screening in Older Adults With Type 2 DM

[The role of candidate genes in susceptibility to diabetic nephropathy].

[Experimental study of the effect of physiologically active combinations on the stimulation of reparative osteogenesis].

Quantum transport through a periodic scatterer in a magnetic field.